Literature DB >> 25522005

A convergent approach to the total synthesis of telmisartan via a Suzuki cross-coupling reaction between two functionalized benzimidazoles.

Alex D Martin1, Ali R Siamaki, Katherine Belecki, B Frank Gupton.   

Abstract

A direct and efficient total synthesis has been developed for telmisartan, a widely prescribed treatment for hypertension. This approach brings together two functionalized benzimidazoles using a high-yielding Suzuki reaction that can be catalyzed by either a homogeneous palladium source or graphene-supported palladium nanoparticles. The ability to perform the cross-coupling reaction was facilitated by the regio-controlled preparation of the 2-bromo-1-methylbenzimidazole precursor. This convergent approach provides telmisartan in an overall yield of 72% while circumventing many issues associated with previously reported processes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25522005     DOI: 10.1021/jo5025333

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  4 in total

1.  Chlorodifluoromethane as a C1 Synthon in the Assembly of N-Containing Compounds.

Authors:  Xingxing Ma; Jianke Su; Xingang Zhang; Qiuling Song
Journal:  iScience       Date:  2019-07-08

2.  An improved synthesis of telmisartan via the copper-catalyzed cyclization of o-haloarylamidines.

Authors:  Junchi Zhang; Rui Li; Fuqiang Zhu; Changliang Sun; Jingshan Shen
Journal:  RSC Adv       Date:  2020-04-03       Impact factor: 3.361

Review 3.  Rational Design and Synthesis of AT1R Antagonists.

Authors:  Nikitas Georgiou; Vasileios K Gkalpinos; Spyridon D Katsakos; Stamatia Vassiliou; Andreas G Tzakos; Thomas Mavromoustakos
Journal:  Molecules       Date:  2021-05-14       Impact factor: 4.411

4.  7-Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir.

Authors:  Robert E Ziegler; Bimbisar K Desai; Jo-Ann Jee; B Frank Gupton; Thomas D Roper; Timothy F Jamison
Journal:  Angew Chem Int Ed Engl       Date:  2018-05-14       Impact factor: 15.336

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.